On April 21, 2026, Amazon launched a comprehensive GLP-1 weight management program through One Medical, integrating Wegovy, Foundayo, and Eli Lilly weight-loss drug access with Amazon Pharmacy fulfillment and One Medical's 200-plus brick-and-mortar primary-care clinics. By the close of trading on April 28, Hims & Hers Health (NYSE: HIMS) had fallen approximately 4% as investors digested the competitive risk of a vertically integrated Amazon stack hitting the same telehealth-plus-Rx market that Hims and Ro have built billion-dollar businesses around.

Why It Matters

The Amazon One Medical entry is the clearest signal yet that telehealth's brand-only flywheel is closing. Hims, Ro, and BlueChew built businesses on the premise that direct-to-consumer Rx + light medical infrastructure could outperform legacy pharmacy on convenience and price. Amazon now matches them on convenience (One Medical + same-day Rx delivery), beats them on price ($25-$74 vs. $149+), and adds the in-person clinic option neither Hims nor Ro can match. For sex tech and sexual-health DTC: this is a structural margin pressure event, not just a one-quarter stock dip — and it lands while Hims is simultaneously absorbing the April 2 customer-support data breach, the FDA peptide review trajectory, and the ongoing tariff cost-pass-through. Watch for sexual-health specialty (ED, hair, menopause, peptides) to consolidate fast as scale economics shift toward Amazon's platform.

Pricing is the headline. Amazon One Medical's GLP-1 program runs as low as $25/month for insured patients on top of the $9/month Prime member One Medical add-on (or $99/year). That stack lands well below Hims's $39 first-month / $149 ongoing GLP-1 Body Membership pricing and just below Ro's recently announced $39 first month / $149 monthly tier. Amazon also undercuts both on logistics: same-day GLP-1 delivery now reaches nearly 3,000 cities, with a stated expansion to 4,500 by year-end. The pure-play telehealth competitors do not have an equivalent same-day delivery offering at scale.

For male sexual health specifically — Hims's anchor category alongside hair loss and now GLP-1 — the read-through is more nuanced than headline stock movement suggests. GLP-1 cross-sell and shared infrastructure (the same medical-record platform, the same compounding pharmacies, the same prescription-fulfillment logistics) underpin Hims's unit economics on its lower-margin ED telehealth business. Aggressive pricing on GLP-1 forces Hims to defend market share at thinner margins, which compresses cross-subsidy capacity for ED, hair, and the recently launched menopause and peptide expansions. Ro's April 23 GLP-1 price cut to $39 first month / $74 annual / $149 monthly already pre-empted Amazon's pressure; Hims's May 11 earnings report becomes the next pricing-discipline tell.

Sources

Update — 2026-04-29

Initial entry — story first created.